By using foundation models to analyze vast datasets, companies can create a synthetic 'standard of care' arm for single-arm Phase 1 trials. The AI matches patients based on deep clinical and genomic parameters, providing insights comparable to a much larger Phase 3 trial.

Instead of relying on often unavailable direct enrollment data, the AI system identifies sites repeatedly chosen by the same sponsor for similar trials. This pattern serves as a powerful, indirect indicator of successful past performance and high-quality operations, offering a more nuanced view than simply counting patients.

Beyond early discovery, LLMs deliver significant value in clinical trials. They accelerate timelines by automating months of post-trial documentation work. More strategically, they can improve trial success rates by analyzing genomic data to identify patient populations with a higher likelihood of responding to a treatment.

Unlike image recognition or NLP, clinical trial data possesses a unique and complex mathematical geometry. According to Dr. Juraji, this means generic AI models are insufficient. Solving trial failures requires specialized AI built to navigate this specific, difficult data landscape.

The FDA is abandoning rigid, fixed-length clinical trials for a "continuous" model. Using AI and Bayesian statistics, regulators can monitor data in real-time and approve a drug the moment efficacy is proven, rather than waiting for an arbitrary end date, accelerating access for patients.

Regulators like the FDA are actively encouraging the use of AI to improve clinical trial success rates. However, pharmaceutical companies are hesitant to adopt these innovative methods, fearing that any deviation from traditional processes will lead to costly delays or orders to restart the trial.

Despite a threefold increase in data collection over the last decade, the methods for cleaning and reconciling that data remain antiquated. Teams apply old, manual techniques to massive new datasets, creating major inefficiencies. The solution lies in applying automation and modern technology to data quality control, rather than throwing more people at the problem.

While most focus on AI for drug discovery, Recursion is building an AI stack for clinical development, where 70% of costs lie. By using real-world data to pinpoint patient locations and causal AI to predict responders, they are improving trial enrollment rates by 1.5x. This demonstrates a holistic, end-to-end AI strategy that addresses bottlenecks across the entire value chain, not just the initial stages.

Instead of a total overhaul, we can accelerate trials with three changes: 1) A simple patient opt-in registry for trial participation. 2) Collaborative platform trials testing multiple drugs against one control group. 3) A shared database for all trial data, including failures.